Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://ashleyj531dff1.wikicorrespondent.com/user